TL;DR
The U.S. has withheld nearly $600 million from Gavi, the global vaccine alliance, amid disputes over vaccination policies. This could impair immunization efforts in poorer nations, risking increased disease outbreaks.
The United States is currently withholding approximately $600 million in funding from Gavi, the global vaccine alliance, amid disputes over vaccine policies and concerns about vaccine safety. This move threatens to undermine immunization efforts in lower-income countries, where Gavi’s support is vital, and represents a significant shift in U.S. engagement with global health initiatives.
Since late 2024, the U.S. has not disbursed nearly $600 million allocated for Gavi, despite congressional approval and previous commitments. The State Department and the Department of Health and Human Services cite a lack of detailed data and transparency from Gavi as reasons for the holdback. This delay comes amid broader tensions over vaccine strategies, including opposition to the use of older, cheaper vaccines containing thimerosal and the diphtheria-tetanus-pertussis (DTwP) vaccine, which some U.S. officials and officials like Robert F. Kennedy Jr. have criticized without scientific basis.
Gavi, which the U.S. helped establish and has historically been its largest donor, relies heavily on U.S. funding to support immunization programs in over 70 countries. The withheld funds represent roughly 13% of Gavi’s expected revenue through 2030. Experts warn that this financial gap could lead to reduced vaccine coverage, increased disease outbreaks, and preventable deaths, especially in impoverished regions where access to newer, more expensive vaccines is limited.
Why It Matters
This development is significant because it risks reversing progress in global vaccination efforts, potentially leading to outbreaks of preventable diseases such as measles, diphtheria, and pertussis. The U.S. is a key supporter of Gavi, and its withdrawal of funds signals a shift in its commitment to international health initiatives. The move could also influence other donors and impact the stability of global immunization programs, with the poorest populations suffering the most.
Vaccination Record: Vaccine for adolescents and adults (Diphtheria – Tetanus – Poliomyelitis – Pertussis-Measles – Mumps – Rubella – Meningitis C – HPV – H epatitis B – Flu …)
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background
Historically, the U.S. has been a major funder of Gavi, contributing nearly $1.6 billion in 2024. The current withholding began after disagreements over vaccine ingredients and safety policies, including opposition to the use of thimerosal and older vaccines like DTwP, which remain crucial in low-resource settings. The Biden administration’s stance aligns with broader domestic debates on vaccine safety and policy, but contrasts with WHO recommendations and global health priorities. Previous efforts to reform vaccine strategies have faced resistance from some U.S. officials, complicating international cooperation.
“Using cheaper vaccines like DTwP is essential in low-resource settings, even if they have some short-term side effects, because they provide long-lasting protection and require fewer doses.”
— Seth Berkley, infectious-disease expert and former Gavi leader
“President Trump entrusted Secretary Robert F. Kennedy Jr. to manage the U.S. relationship with Gavi, and we are awaiting detailed data to evaluate U.S. support.”
— U.S. State Department spokesperson
“We are cautiously optimistic about a constructive path forward, but Gavi has yet to provide the specific data needed for U.S. support.”
— Andrew Nixon, HHS Deputy Assistant Secretary for Media Relations
multi-dose vaccine for low-resource settings
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What Remains Unclear
It remains unclear whether the U.S. will release the withheld funds soon or if the dispute over vaccine policies will be resolved. The impact of the funding delay on Gavi’s ongoing programs and global immunization rates is still being assessed, and international health experts warn that the situation could worsen if the deadlock persists.
AUTISM. AUTISM SPECTRUM DISORDERS EVERYTHING THEY DON'T WANT YOU TO KNOW. Is there a relationship between vaccines and autism? Dedicated to … to live better and free yourself from drugs)
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What’s Next
Next steps include ongoing negotiations between U.S. officials and Gavi, with potential for the release of funds if transparency and policy concerns are addressed. Watch for congressional hearings and international statements clarifying the U.S. stance and plans for future support. Gavi may also seek alternative funding sources to mitigate the impact of the U.S. withholding.
global vaccination support supplies
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Why has the U.S. withheld funding from Gavi?
The U.S. cites a lack of detailed data and transparency from Gavi regarding vaccine safety policies and ingredient use, particularly concerning older vaccines like DTwP and thimerosal-containing vaccines.
What impact could this have on global vaccination efforts?
The delay in funding threatens to reduce vaccine coverage in low-income countries, potentially leading to outbreaks of preventable diseases and increased child mortality.
Is this affecting vaccination in the U.S.?
No, the dispute primarily concerns international vaccine programs. Domestic vaccination efforts are not directly impacted by this funding delay.
Could the U.S. change its position and release the funds?
Yes, ongoing negotiations suggest that the U.S. may release funds if Gavi provides the necessary data and agrees to certain policy changes, but no definitive resolution has been announced.
Source: The Atlantic
